Spagnolo Ferdinando, Brugiapaglia Silvia, Perin Martina, Intonti Simona, Curcio Claudia
Department of Molecular Biotechnology and Health Sciences, University of Turin, Piazza Nizza 44bis, 10126 Turin, Italy.
School of Advanced Defence Studies, Defence Research & Analysis Institute, Piazza della Rovere 83, 00165 Rome, Italy.
Pharmaceutics. 2025 May 4;17(5):610. doi: 10.3390/pharmaceutics17050610.
In recent years, there has been an exponential growth in global anti-cancer drug research, prompting the necessity for comprehensive analyses of publication output and thematic shifts. : This study utilized a comprehensive set of PubMed records from 1962 to 2024 and examined growth patterns, content classification, and co-occurrence of key pharmacological and molecular terms. : Our results highlight an exponential rise in publications, with an annual compound growth rate of over 14%, influenced by advancements in digital knowledge sharing and novel therapeutic breakthroughs. A pronounced surge occurred during the COVID-19 pandemic, suggesting a sustained shift in research dynamics. The content analyses revealed a strong emphasis on classical chemotherapeutic agents-often studied in combination with targeted therapies or immunotherapies-and a growing focus on immune checkpoint inhibitors and vaccine platforms. Furthermore, co-occurrence networks indicated robust links between chemotherapy and supportive care, as well as emerging synergies between immuno-oncology, precision medicine approaches. : Our study suggests that while novel modalities are reshaping treatment paradigms, chemotherapy remains central, underscoring the value of integrative regimens. This trend toward personalized, combination-based strategies indicates a transformative era in oncology research, where multidimensional data assessment is instrumental in guiding future therapeutic innovations.
近年来，全球抗癌药物研究呈指数级增长，这促使有必要对发表成果和主题转变进行全面分析。本研究利用了1962年至2024年的一组全面的PubMed记录，研究了增长模式、内容分类以及关键药理学和分子术语的共现情况。我们的结果突出了出版物的指数级增长，年复合增长率超过14%，这受到数字知识共享进步和新型治疗突破的影响。在新冠疫情期间出现了明显的激增，这表明研究动态发生了持续转变。内容分析显示，研究重点强烈集中在经典化疗药物上（这些药物通常与靶向治疗或免疫治疗联合研究），并且越来越关注免疫检查点抑制剂和疫苗平台。此外，共现网络表明化疗与支持性护理之间存在紧密联系，免疫肿瘤学、精准医学方法之间也出现了新的协同作用。我们的研究表明，虽然新的治疗方式正在重塑治疗模式，但化疗仍然是核心，这凸显了综合治疗方案的价值。这种向个性化、基于联合治疗的策略发展的趋势表明肿瘤学研究进入了一个变革时代，在这个时代，多维度数据评估有助于指导未来的治疗创新。
